‹ ›
MYP_016061
← PREVIOUS NEXT → BACK
Basic Information
EK1C4
Anticancer
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Standard
41 amino acids
C208H336N48O71S
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG
Physicochemical Analysis
4677.24 Da
4.36
-5.52
-5.76
-0.1347
-0.45
0.75
-0.02
21.17
104.63
0.0732
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1958.21
-15.67
66.0
67.0
168.0
328.0
3.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0408569 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-Chol
PEG4-Chol
Bio-Activity Profile
Antiviral Fusion inhibition
CoV-SHC014 | Huh-7 cells
0.0043 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. | Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L. | Cell Res. 2020 Apr;30(4):343-355. | DOI:10.1038/s41422-020-0305-x | PMID:32231345 PMID32231345 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32231345/
RECORD: Rec_0411579 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-Chol
PEG4-Chol
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of cell-cell infusion in Caco2 cells
0.00863 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0420798 VERIFIED: YES
Provenance & Taxonomy
Human coronavirus OC43 [Virus]
HR2-derived fusion inhibitor
31631
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Cholesterol conjugation
PEG4 spacer
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome-like coronavirus Rs3367
0.0669 μM
IC50
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion PMID32231345 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32231345/
RECORD: Rec_0420907 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG4-Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2 Cytotoxic
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. PMID: 32231345 PMID35087243;32231345 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0426344 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-Chol
PEG4-Chol
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of cell-cell infusion in Caco2 cells
0.08538 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
FIRST PREV 1 ... 34 35 36
Showing 5 records · Page 36 of 36